Notice of Award of a Single-Source Cooperative Agreement To Fund the National AIDS Control Committee (NACC), Cameroon, 12967-12968 [2022-04788]
Download as PDF
Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices
• HIV prevention services: Voluntary
medical male circumcision; Cervical
cancer prevention and treatment;
Gender based violence Prevention and
response; Condom programming; Preexposure prophylaxis; Elimination of
mother-to-child transmission; Support
for Key and vulnerable populations and
Orphans and vulnerable children;
• HIV treatment and support services
for all age groups across the care
continuum from case finding to viral
load suppression. Support will include:
Prevention and management of
opportunistic infections and advanced
HIV disease, as well as noncommunicable diseases (including
support for mental health);
• Health system strengthening
including support to financial and
administrative management systems,
internal controls, human resources for
health, health information systems,
supply chain/commodities
management, laboratory services, and
continuous quality improvement.
The Provincial Health Offices are the
single entities eligible for this award
since they are the sole government
institutions with the mandate to support
health service delivery through capacity
building, systems strengthening, and
oversight for HIV program
implementation for the population of
Zambia per the National Health Policy
and Zambian National Health Strategic
Plan.
lotter on DSK11XQN23PROD with NOTICES1
Summary of the Award
Recipient: Southern Provincial Health
Office; Lusaka Provincial Health Office;
Western Provincial Health Office; and
Eastern Provincial Health Office in
Zambia.
Purpose of the Award: The purpose of
this award is to provide PHOs with CDC
technical assistance and financial
support to maintain and sustain the
province’s overall leadership and
oversight for implementing high-impact
HIV combination prevention, treatment,
and support services, including clinical,
surveillance, and laboratory services as
well as to identify and mitigate
emerging disease threats for PLHIV.
Specifically, it will serve to strengthen
capacity development activities, while
providing optimal health systems
strengthening in support of continued
and sustainable HIV epidemic control in
Zambia.
Amount of Award: The approximate
year 1 funding amount in Federal Fiscal
Year (FFY) 2022 funds will be, subject
to the availability of funds:
• Southern Provincial Health Office
(SPHO): Anticipated Year 1 Funding
Amount is $14,500,000
VerDate Sep<11>2014
17:25 Mar 07, 2022
Jkt 256001
• Lusaka Provincial Health Office
(LPHO): Anticipated Year 1 Funding
Amount is $19,000,000
• Western Provincial Health Office
(WPHO): Anticipated Year 1 Funding
Amount is $12,000,000
• Eastern Provincial Health Office
(EPHO): Anticipated Year 1 Funding
Amount is $12,000,000;
Funding amounts for years 2–5 will be
set at continuation.
Authority:This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003).
Period of Performance: September 30,
2022, through September 29, 2027.
Dated: March 2, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–04827 Filed 3–7–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Single-Source
Cooperative Agreement To Fund the
National AIDS Control Committee
(NACC), Cameroon
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $3,000,000 for
Year 1 of funding to the National AIDS
Control Committee (NACC), Cameroon.
The award will strengthen national
policies, build capacity, and define
high-level high-impact interventions
and key strategies for HIV/TB
prevention, treatment and care in
Cameroon. Funding amounts for years
2–5 will be set at continuation.
DATES: The period for this award will be
September 30, 2022, through September
29, 2027.
FOR FURTHER INFORMATION CONTACT: Lisa
Esapa, Center for Global Health, Centers
for Disease Control and Prevention,
Standard Chartered Bank Building,
Hippodrome, Telephone: 800–232–
6348, Email: hww5@cdc.gov.
SUPPLEMENTARY INFORMATION: The
single-source award will implement HIV
prevention, care and treatment in
Cameroon through activities, including:
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
12967
Developing and implementing policies
and strategies to optimize case finding,
HIV treatment and retention, viral load
coverage and suppression, and building
workforce capacity to improve uptake
and quality of these HIV/TB services;
and enhancing the implementation of
evidence-based prevention
interventions for KPs (key populations)
/PPs (priority populations) /GP (general
populations. Implementation of this
award will enhance scale up of services
and improve quality of diagnostics,
treatment, management, and clinical
outcomes for HIV and TB infections in
Cameroon. This award will build upon
CDC’s initial successful partnerships to
address these challenges and gaps and
complement Global Fund efforts. NACC
is in a unique position to conduct this
work, as it is the organization mandated
by the Government of Cameroon to
coordinate HIV/AIDS activities in
Cameroon. NACC is essential to
building effective national-level
coordination in HIV programs, as
mandated in the 2000–2005 and 2006–
2010 National HIV/AIDS Strategic
Plans. The mission of NACC is to
coordinate a comprehensive and
effective multi-sector and decentralized
national response to HIV/AIDS,
including coordination and support to
the health sector response.
Summary of the Award
Recipient: National AIDS Control
Committee (NACC), Cameroon.
Purpose of the Award: The purpose of
this award is to strengthen national
policies and define high-level highimpact interventions and key strategies
for HIV/TB prevention, treatment and
care; improve knowledge and prevent
high risk behaviors associated with
STIs/HIV; monitor and ensure the
elimination of user fees for all HIV/TB
services; develop national quality
improvement policy and setup CQI
management system; provide technical
capacity to generate quality data; reduce
HIV/TB related morbidity and mortality;
and provide capacity to coordinate and
monitor the national HIV response in
Cameroon.
Amount of Award: The approximate
year 1 funding amount will be $
3,000,000 in Federal Fiscal Year (FYY)
2022 funds, subject to the availability of
funds. Funding amounts years 2–5 will
be set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003).
Period of Performance: September 30,
2022, through September 29, 2027.
E:\FR\FM\08MRN1.SGM
08MRN1
12968
Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices
Dated: March 2, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2022–04788 Filed 3–7–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: NCGC00413972 and Its
Related Analogs Consisting of an
Imidazo-Pyrazine Scaffold Core for the
Treatment or Prevention of Cancers
Expressing the Mannose Receptor
CD206, Including Both Solid Tumors
and Hematological Malignancies
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patent Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Macala Bio, Inc. located in
1000 NW Wall Street, Suite 220, Bend,
OR 97703.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before March 23, 2022 will be
considered.
SUMMARY:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Eric Cheng, Ph.D., Licensing
and Patenting Manager at (240)-276–
5530 or eric.cheng2@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
lotter on DSK11XQN23PROD with NOTICES1
United States Provisional Patent
Application No. 62/950,488, filed 19
December 2019 and entitled ‘‘CD206
Modulators Their Use And Methods For
Preparation’’ [HHS Reference No. E–
105–2019/0–US–01];
PCT Patent Application PCT/US2020/
065238, filed 16 December 2020 and
entitled ‘‘CD206 Modulators Their Use
And Methods For Preparation’’ [HHS
Reference No. E–105–2019–0–PCT–02].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
17:25 Mar 07, 2022
Dated: March 2, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2022–04829 Filed 3–7–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Intellectual Property
VerDate Sep<11>2014
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to:
NCGC00413972 and its related analogs
consisting of an imidazo-pyrazine
scaffold core for the treatment or
prevention of cancers expressing the
mannose receptor CD206, including
both solid tumors and hematological
malignancies.
This technology discloses
immunotherapy drugs, and to
compounds that modulate CD206 as
well as their use and methods for
preparation.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Jkt 256001
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request Generic Clearance
for National Cancer Institute (NCI) NCI
Resources, Software and Data Sharing
Forms (National Cancer Institute)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Diane Kreinbrink, Office of
Management Policy and Compliance,
National Cancer Institute, 9609 Medical
Center Drive, Rockville, Maryland, 208
or call non-toll-free number (240) 276–
7283 or email your request, including
your address to: diane.kreinbrink@
nih.gov. Formal requests for additional
plans and instruments must be
requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on December 20, 2021 (Vol. 86
FR 71901) and allowed 60 days for
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Cancer Institute (NCI), National
Institutes of Health (NIH), may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid Office of Management
and Budget (OMB) control number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review
and approval of the information
collection listed below.
Proposed Collection: Generic
Clearance for NCI Resources, Software
and Data Sharing Forms, 0925—NEW,
Expiration Date xx/xx/xxxx, NCI, NIH.
Need and Use of Information
Collection: In preparation for
dissemination and sharing of data sets,
forms requesting or applying for access,
upload, share, and store data will be
needed. The purpose of data sharing
E:\FR\FM\08MRN1.SGM
08MRN1
Agencies
[Federal Register Volume 87, Number 45 (Tuesday, March 8, 2022)]
[Notices]
[Pages 12967-12968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04788]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the National AIDS Control Committee (NACC), Cameroon
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $3,000,000 for Year 1 of funding to the National
AIDS Control Committee (NACC), Cameroon. The award will strengthen
national policies, build capacity, and define high-level high-impact
interventions and key strategies for HIV/TB prevention, treatment and
care in Cameroon. Funding amounts for years 2-5 will be set at
continuation.
DATES: The period for this award will be September 30, 2022, through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Lisa Esapa, Center for Global Health,
Centers for Disease Control and Prevention, Standard Chartered Bank
Building, Hippodrome, Telephone: 800-232-6348, Email: [email protected].
SUPPLEMENTARY INFORMATION: The single-source award will implement HIV
prevention, care and treatment in Cameroon through activities,
including: Developing and implementing policies and strategies to
optimize case finding, HIV treatment and retention, viral load coverage
and suppression, and building workforce capacity to improve uptake and
quality of these HIV/TB services; and enhancing the implementation of
evidence-based prevention interventions for KPs (key populations) /PPs
(priority populations) /GP (general populations. Implementation of this
award will enhance scale up of services and improve quality of
diagnostics, treatment, management, and clinical outcomes for HIV and
TB infections in Cameroon. This award will build upon CDC's initial
successful partnerships to address these challenges and gaps and
complement Global Fund efforts. NACC is in a unique position to conduct
this work, as it is the organization mandated by the Government of
Cameroon to coordinate HIV/AIDS activities in Cameroon. NACC is
essential to building effective national-level coordination in HIV
programs, as mandated in the 2000-2005 and 2006-2010 National HIV/AIDS
Strategic Plans. The mission of NACC is to coordinate a comprehensive
and effective multi-sector and decentralized national response to HIV/
AIDS, including coordination and support to the health sector response.
Summary of the Award
Recipient: National AIDS Control Committee (NACC), Cameroon.
Purpose of the Award: The purpose of this award is to strengthen
national policies and define high-level high-impact interventions and
key strategies for HIV/TB prevention, treatment and care; improve
knowledge and prevent high risk behaviors associated with STIs/HIV;
monitor and ensure the elimination of user fees for all HIV/TB
services; develop national quality improvement policy and setup CQI
management system; provide technical capacity to generate quality data;
reduce HIV/TB related morbidity and mortality; and provide capacity to
coordinate and monitor the national HIV response in Cameroon.
Amount of Award: The approximate year 1 funding amount will be $
3,000,000 in Federal Fiscal Year (FYY) 2022 funds, subject to the
availability of funds. Funding amounts years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003).
Period of Performance: September 30, 2022, through September 29,
2027.
[[Page 12968]]
Dated: March 2, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-04788 Filed 3-7-22; 8:45 am]
BILLING CODE 4163-18-P